Senior Research Officer
Dr Marina Pajic completed her PhD in the laboratory of Prof Michelle Haber at the Children’s Cancer Institute (CCI), University of New South Wales, where she investigated chemoresistance mechanisms in childhood cancers, supported by a University Postgraduate Award and a CCI Postgraduate Scholarship. On completion of her PhD Dr Pajic joined the renowned group of Prof Piet Borst at the Netherlands Cancer Institute where she established physiologically-relevant mouse models to study mechanisms of chemoresistance in breast cancer. This project resulted in funding approval from the Dutch government and key first and co-author publications.
In 2010, Dr Pajic moved back to Australia to join the Pancreatic Cancer Research Team and the Australian Pancreatic Cancer Genome Initiative (APGI) at the Garvan Institute for Medical Research. As part of the International Cancer Genome Consortium sequencing effort, Dr Pajic has established a unique personalised medicine project for pancreatic cancer and since 2013 leads the Personalised Cancer Therapeutics Group.
She has been awarded three fellowships from the Cancer Institute New South Wales (Early Career (2011) and Career Development Fellowships (2013 and 2016)) and a Philip Hemstritch fellowship in pancreatic cancer. She takes an active role in training emerging scientists (Honours and PhD projects), with all students currently supported by Sydney Catalyst, NHMRC and UNSW scholarships. Dr Pajic engages and communicates regularly with the public through the Institute’s open events. She is an independent reviewer for several journals, an EACR ambassador and co-director of the Australasian Pancreatic Club.
In the NewsThe importance of returning research results to study participants - Oct 10, 2017
Biosensor mouse lights up health and disease - Oct 06, 2017
A one-two punch for pancreatic cancer: ‘softening’ tumours before chemo markedly improves survival - Apr 06, 2017
NSW Government funding for Garvan scientists to research new treatments for breast and pancreatic cancer - Feb 17, 2017
The ‘other’ pancreatic cancer: uncovering the genomic landscape of an enigmatic rare tumour - Feb 16, 2017
NHMRC funding success for Garvan researchers - Nov 09, 2015
Garvan Institute scientists receive $10.7 million in NHMRC funding - Oct 22, 2014
Mark Cowley and Marina Pajic top-ranked applicants for Cancer Institute NSW Fellowships - Apr 08, 2014
International team reveals 21 ‘signatures’ in 30 common cancers - Aug 15, 2013
Awards and Honours
2016-Cancer Institute New South Wales (CINSW) Career Development Fellowship (sole CI)
2016- Cancer Council New South Wales Project Grant (CIB)
2015- Cancer Australia and NHMRC Project Grant Approvals as Chief Investigator (CIA and CID).
2015- Avner Pancreatic Cancer Foundation "Woolies on Wheels" Innovation Grant as Principal Investigator
2014- Three NHMRC Project Grant Approvals (CIA, B and D)
2014- NBCF Innovator Grant (CIB)
2013– Cancer Australia Project Grant (CIA)
2013- CINSW Career Development Fellowship (sole CI)
2013- Cancer Council NSW Project Grant (CID)
2013 – Travel Grants (CASS Foundation, Sydney Catalyst)
2012-2013 – Conference Awards (EACR Cancer Genomics Conference, Cambridge, UK; Australian Division of International Academy of Pathology - 38th annual scientific meeting, Australia; EACR 22nd Biennial Congress, Barcelona, Spain)
2012 and 2015 – CINSW Wildfire Award (Group Award)
2012-Present – European Association for Cancer Research (EACR) ambassador
2012-Present– Australasian Pancreatic Club (APC) Executive council member
2011-Present– Phillip Hemstritch fellowship in pancreatic cancer
2011-2013– CINSW early career development fellowship
2003– University Postgraduate Award (University of Sydney) and Children’s Cancer Institute of Australia Postgraduate Scholarship (University of New South Wales)
2002– Postgraduate Scholarship in Cellular Cancer Pharmacology (University of Sydney)
2001– University postgraduate bursary award (University of Auckland)
2001 – MSc (with Honours) in Pharmacology, University of Auckland, Auckland - New Zealand
1999 – BSc in Pharmacology, University of Auckland, Auckland - New Zealand
Vennin C, Chin VT, Warren S, Lucas MC, Herrmann D, Melenec P, Walters SN, Magenau A, Allam AH, McCloy RA, Conway JRW, Pinese M, Boulghourjian A, Zaratzian A, Heu C, Nagrial AM, Chou A, Steinmann A, Drury A, Froio D, Giry-Laterriere M, Harris NLE, Mcghee EJ, Whan R, Grey S, Johns AL, Samra JS, Chantrill L, Gill AJ, Biankin AV, APGI, Wang Y, Evans TRJ, Anderson KI, Samuel MS, Burgess A, Sansom OJ, Morton JP, Pajic M*, Timpson P*. * Co-last and co-corresponding authors. Science Translational Medicine 2017 9(384). pii: eaai8504. Study further highlighted by Cancer Discovery, Nature Reviews Gastroenterology and Hepatology, Nature Reviews Clinical Oncology and article in New Scientist magazine.
Pajic M, Blatter S, Guyader C, Gonggrijp M, Kersbergen A, Sol1 W, Drost R, Jonkers J, Borst P, Rottenberg S. Selected alkylating agents can overcome drug tolerance of G0-1 like tumor cells and eradicate BRCA1-deficient mammary tumors in mice. Clinical Cancer Research 2017 (Accepted 23rd June)
Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Nagaraj SH, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Davì MV, Landoni L, Malpaga A, Miotto M, Whitehall VL, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M et al Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017 543(7643):65-71
Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016 531(7592):47-52
Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015 518(7540):495. * Significant national coverage, including interviews with Dr Pajic for SBS and Channel 7 national news.
Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M et al Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research 2015 21(9):2029.
Al-Ejeh F, Pajic M, Shi W, Kalimutho M, Miranda M, Nagrial AM, Chou A et al. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research 2014 20(12):3187.
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio S, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale A-L, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörð JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinsk M, Jäger N, Pajic M. et al. Signatures of mutational processes in human cancer. Nature 2013; 500(7463):415-21
Chang DK, Johns AL, Scarlett CJ, Pajic M. et al. Molecular Pathological Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. Journal of Clinical Oncology 2013; 31(10):1348-56
Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M. et al. Genomic Analysis Reveals Roles for Chromatin Modification and Axon Guidance in Pancreatic Cancer. Nature 2012; 491(7424):399-405 IF 36.3
Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, ten Hoeve JJ, de Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM; Australian Pancreatic Cancer Genome Initiative, Pajic M et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012; 486(7402):266-70
Pajic M, Murray J, Marshall GM, Cole SP, Norris MD, Haber M. ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript. Pharmacogenetics and Genomics 2011; 21(5):270
Pajic M, Kersbergen A, van Diepen F et al. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. Cell Cycle 2010; 9(18):3780
Pajic M, Iyer JK, Kersbergen A, et al. A moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer Cancer Research 2009; 69 16:6396
Rottenberg S, Nygren AOH, Pajic M et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sc USA 2007; 104(29):12117